Korsana Biosciences (KRSA) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.41B and a free-cash-flow yield of 0.0%. Nama's AI scorecard rates it Hold, 4.8 out of 10. On 12-month momentum it ranks in the leading band of its market.
AI scorecard
Hold · 4.8/10
The sections balance. As of Nov 7, 2026.
Momentum
Leading · +167.6% over 12 months ex. last
Top 20% of its market on the past year's steady rise.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-92.6%
How far the last close sits under the highest price of the past five years.
Market cap
$1.41B
Trailing P/E
—
Price / book
—
Price / sales
—
FCF yield
0.0%
Dividend yield
—
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
1.7
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
KRSA earnings
Beat the EPS estimate in 2 of 2 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q4 2025
Mar 31, 2026
-$0.19
-$0.38
+50.0%
—
Q3 2022
Nov 3, 2022
-$0.24
-$0.35
+31.4%
—
KRSA analyst price target
Median target $44.00 from 5 analysts, ranging $8.00 – $70.00.
Nama's AI scorecard currently rates Korsana Biosciences Hold (4.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is the KRSA price target?
The median analyst price target from 5 analysts is $44.00, with a range of $8.00 – $70.00.
Is KRSA Shariah compliant?
Nama's AAOIFI-style screen reads Korsana Biosciences as Can't Tell. A figure the screen needs is missing, so it can't tell.